Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Microfluidic avidity platform for preclinical cell therapy validation
Avigen is a contract research organisation providing preclinical validation services for cellular immunotherapies using a proprietary microfluidic platform. The platform measures cellular avidity, the total binding strength between immune and cancer cells, at high throughput using fluid shear stress, enabling…
Clinical-stage company developing radioligand cancer therapies
Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer. Its pipeline centres on prostate-specific membrane antigen-targeted radioligand therapies using both beta- and alpha-emitting radionuclides, designed to deliver high radiation doses to tumour…
Clinical-stage oncology company advancing in-licensed cancer drug assets
Ellipses Pharma is a clinical-stage oncology drug development company that in-licenses cancer drug assets from academia and industry, advances them through clinical trials using a continuous funding model, and out-licenses at value-inflection points. Its pipeline spans small molecule kinase inhibitors, selective…
Blood-based CIZ1B biomarker test for early-stage lung cancer detection
Cizzle Biotechnology is a UK-based diagnostics company developing a non-invasive blood test for the early detection of lung cancer. The company's CIZ1B biomarker test identifies a stable plasma biomarker highly correlated with early-stage disease, offering an alternative to imaging or biopsy procedures. Cizzle's test…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
3D immune-microtumour platform for cancer treatment selection
Pear Bio is a biotechnology company that tests cancer treatment efficacy directly on patient-derived tumour samples using three-dimensional immune-microtumour cultures and computer vision analysis. By culturing tumour biopsies with matched patient immune cells and imaging drug effects over time, the platform generates…
Clinical-stage precision oncology developing first-in-class TACC3 inhibitor therapeutics
Coiled Therapeutics is a UK-listed, clinical-stage oncology company developing precision cancer therapeutics against structurally complex, previously undruggable targets. Its lead candidate, AO-252, is a first-in-class, orally administered small molecule inhibitor of TACC3 currently in Phase I trials for advanced…
Long-read RNA sequencing platform for cancer biomarker discovery and diagnostics
Wobble Genomics is a Scottish biotechnology company developing long-read RNA sequencing technologies for biomarker discovery and cancer diagnostics. Its core platform combines a biochemical method to enrich rare and low-abundance full-length RNA transcripts, with a bioinformatics pipeline for novel transcript…
Non-endoscopic molecular diagnostics for early oesophageal cancer detection
Cyted Health is a gastrointestinal molecular diagnostics company developing minimally invasive testing for early detection and monitoring of oesophageal pre-cancer and cancer. Its platform combines a swallowable capsule sponge cell collection device with AI-driven biomarker molecular assays to detect Barrett's…
Phenotypic screening platform for targeted protein degradation drug discovery
PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets. The platform systematically unmasks cryptic binding sites across the human proteome and links them to therapeutic functions in a live-cell context, enabling the discovery…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City Place in London, the UK operation employs approximately 1,300 people and focuses on commercialisation, medical affairs, regulatory…
Mitochondrial DNA liquid biopsy tests for cancer and disease detection
MDNA Life Sciences is a biotechnology company developing proprietary diagnostic tests based on mitochondrial DNA biomarkers. Its technology detects specific mitochondrial DNA deletions in blood and tissue samples as indicators of disease, enabling non-invasive testing for conditions that are difficult to diagnose.…
Raman spectroscopy blood test for early cancer detection
CanSense is a Welsh biotechnology company developing a non-invasive blood test for the early detection of bowel and other cancers. The platform combines Raman laser spectroscopy with artificial intelligence to identify cancer-associated metabolic signatures in blood, delivering results within 48 hours without…
Personalised cancer treatment selection using in vivo drug screening
Vivan Therapeutics is a London-based biotech developing a personalised cancer therapeutics platform. The company's Personal Discovery Process sequences a patient's tumour genome, engineers those mutations into a fruit fly avatar model, and screens thousands of approved drug combinations at high throughput to identify…
AI-powered digital pathology laboratory services for rapid cancer diagnosis
Inify Laboratories is a digital pathology company providing cancer diagnostic services through a fully digital, AI-supported laboratory workflow. The company processes tissue biopsy samples, generating whole slide images that are analysed by its proprietary AI software before review and reporting by specialist…
Targeted oncology combination therapies in biomarker-defined cancer populations
Mosaic Therapeutics is a Cambridge biotech developing targeted combination therapies for cancer. Its proprietary platform integrates genome-scale CRISPR screening, high-throughput combination drug testing across over 1,300 patient-derived tumour models, and advanced computational analysis to identify synergistic drug…
Gene therapy platform delivering precision cancer treatments
Trogenix is a clinical-stage biotechnology company developing precision gene therapies for aggressive solid tumours. Its platform uses proprietary synthetic super-enhancers, engineered genetic constructs delivered via AAV vectors, to selectively activate in cancer cells and simultaneously trigger tumour cell death and…
Engineered bacterial immunotherapies for solid tumours
Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies using engineered Salmonella strains. Its platform combines synthetic biology with AI-enabled discovery to create programmable bacterial therapeutics that deliver payloads within the tumour microenvironment. The lead programme…
Patient-derived cell models and assays for oncology drug discovery
Dominion Biotech is a Cheshire-based biotechnology company developing patient-derived cell (PDC) models and assays to support oncology drug discovery and development. Working in partnership with cancer hospitals and academic collaborators, the company builds a diverse bank of PDC models reflecting the genetic…